造血与淋巴组织肿瘤患者红细胞的天然免疫黏附功能及对NK细胞杀伤活性的影响

Erythrocyte Native Immune Adhering Function (ENIAF) in Patients with Hematopoietic and Lymphoid Neoplasms and Its Effect on NK Cell Killing Activity

本研究探讨造血与淋巴组织肿瘤患者红细胞天然免疫黏附功能及红细胞对NK细胞杀伤活性的影响。外周血枸橼酸钠抗凝,检测红细胞在自身血浆条件下对K562细胞的免疫黏附并计算黏附率。用MTT法测定红细胞对正常NK细胞杀伤K562细胞活性的影响,并与未加红细胞时进行比较。结果表明:红细胞对K562细胞形成了"玫瑰花"样结合。正常人红细胞对K562细胞的免疫黏附结合率为(15.3±6.4)%,造血与淋巴组织肿瘤患者红细胞对K562细胞的免疫黏附结合率为(7.6±7.0)%,与正常人相比较显著下降(t=3.61,p(0.001)。不加红细胞条件下,正常人外周静脉血NK细胞杀伤K562细胞活性为67%-71%。正常人红细胞明显增加NK细胞杀伤K562细胞活性杀伤率为(14.7±5.2)%,造血与淋巴组织肿瘤患者的红细胞减低NK细胞杀伤K562细胞活性,杀伤率为(4.3±7.6)%,二者比较有显著差异(t=6.73,p(0.0001)。结论:造血与淋巴组织肿瘤患者红细胞对K562细胞的免疫黏附能力下降,正常人红细胞明显增加NK细胞杀伤K562细胞活性,而造血与淋巴组织肿瘤患者的红细胞减低NK细胞杀伤K562细胞活性,原因需进一步研究。

The objective of this study was to investigate the change of native immune adhering function （ENIAF） in self-plasma of patients with hematologic and lymphoid neoplasms and its effect on the killing activity of NK cells. The whole blood was anticoagulated with citric acid. 5 pd precipitated red blood cells and 500 pd plasma of patients or controls were directly mixed with 750 pd quantitative K562 cells at 37℃ for 30 minutes. One K562 cell attached by one or more erythrocytes was counted as one rosette, the ratio of rosettes was calculated. Using K562 cells as target cells, the killing activity of NK cells isolated from normol persons was detected by MTT assay, the change of the killing activity was observed after adding RBCs. The results indicated that the ratio of rosettes formed by RBCs of 21 normal controls and K562 cells was 15.3% ±6.4%, and the ratio of roseffes formed by RBCs of 24 patients and K562 cells was 7.6% ± 7.0%. The ability of ENIAF in patients with hematologic and lymphoid neoplasms was significantly lower than that in healthy individuals （t = 3.61, p 〈 0.001 ）. The killing rate of NK cells in peripheral blood of normal individuols was 67% -71% without adding RBCs, and it increased by 14.7% ±5.2% after adding RBCs of normal controls but decreased by 4.3% ±7.6% with RBCs of patients. It is concluded that the ENIAF of RBCs in patients with hematopoietic and lymphoid neoplasms accompanying the reduction of the killing activity of NK cells to K562 cells, so to detect change of ENIAF may for the assessment of the immunological function of patients with hematopoietic and lymphoid neoplasms.